The above preclinical data suggest that HDAC inhibition may sensitize HPV-negative HNSCC cells to cisplatin, and may suppress the proliferative capacity, and the migratory and invasive potential of HPV-negative HNSCC cells. The gene discussed is HDAC9; the disease is head and neck squamous cell carcinoma.